B-
BiotechTV - News
Jefferies London 2026: Nuvation Bio Founder & CEO David Hung shares an update on the launch of IBTROZI (next-gen ROS1 inhibitor and follow-on pipeline projects
0:00-9:36
He discusses the launch and his thoughts on any future copetitors in the space. Plus an update on the mIDH1 inhibitor safusidenib, and a drug-drug interaction platform that was the basis for founding the company.
Publisher
BiotechTV - News
Link
podcasters.spotify.com/pod/show/biotechtv4/episodes/Jefferies-London-2026-Nuvation-Bio-Founder--CEO-David-Hung-shares-an-update-on-the-launch-of-IBTROZI-next-gen-ROS1-inhibitor-and-follow-on-pipeline-projects-e3sgd7o
Published
November 16, 2026
Duration
10 min
Format
Podcast
Category
Issues · Science
Source
RSS feed
Host
BiotechTV
B-
BiotechTV - News
@biotechtvnews
#nuvationbiofounder #ceodavidhung #genros1inhibitor #lifesciences
